JAM ACAD DERMATOL VOLUME 76, NUMBER 2. Research Letters 351
|
|
- Kelley Tucker
- 6 years ago
- Views:
Transcription
1 JAM ACAD DERMATOL Research Letters 351 Standard step sectioning of skin biopsy specimens diagnosed as superficial basal cell carcinoma frequently yields deeper and more aggressive subtypes To the Editor: Correct diagnosis of superficial basal cell carcinoma (BCC) is essential because of the increase of nonsurgical treatments for this subtype. Histologic confirmation by punch biopsy specimen for BCC diagnosis and its subtype is recommended. Although studies have shown the discordance between punch biopsy specimens and excision, there is a lack of research on the sampling error within punch biopsy specimens. 1,2 Moreover, a standardized method for histologic sectioning punch biopsy specimens is currently missing. The current histologic examination protocol of a 3-mm punch biopsy specimen, suspicious for BCC, at the Radboud University Medical Center (Nijmegen, The Netherlands) consists of evaluation of 2 to 3 hematoxylin-eosin-stained tissue sections (4 m) obtained from 1 level. If a BCC is detected in these sections, no additional levels will be cut. If not, the punch biopsy specimen is cut at 4 additional levels and evaluated. We compared the accuracy of histologic examination of only 1 level with a more extensive step-section method. In addition, we investigated whether tumor thickness ([0.4 mm), ulceration, and adnexal extension are determinants of treatment failure or recurrence in superficial BCCs. 3,4 This retrospective study was approved by the institutional review board of the Radboud University Medical Center, Nijmegen, The Netherlands. In all, 116 superficial BCC punch biopsy specimens, obtained in 2014 to 2015, were cut in 4 additional levels at an interval of 200 m. After every 200 m, 10 sections (4 m) were cut, of which the middle 2 sections were hematoxylin-eosin stained and evaluated. Finally, 5 levels per punch biopsy specimen were histopathologically evaluated (Fig 1). Tumor thickness was evaluated by measuring from the granular layer of the epidermis down to the deepest point of invasion (Breslow depth). Included patients were treated with imiquimod cream (n ¼ 23), 5-fluorouracil (n ¼ 19), excision (n ¼ 50), or methylaminolevulinate photodynamic therapy (MAL-PDT) (n ¼ 24) with a follow-up time until January 29, 2016 (Supplemental Table I). In 22.4% (n ¼ 26) a more aggressive BCC subtype was found in the additional hematoxylineosin-stained sections (Table I, Supplemental Table II, and Supplemental Fig 1). There were 2 clinical recurrences (5-fluorouracil, n ¼ 1, and MAL-PDT, n ¼ 1) and 2 treatment failures (MAL-PDT). In the treatment failure/recurrence group there was 1 underdiagnosed BCC (25%); this was the only superficial BCC thicker than 0.4 mm in this group, whereas none showed presence of ulceration or adnexal extension Fig 1. Histopathological examination method of a punch biopsy specimen suspicious for basal cell carcinoma. Schematic overview of the histopathological examination process. The dimensions of the punch biopsy specimen might be smaller than depicted in this figure because of shrinkage after formalin fixation and histologic processing, embedding, and mounting. X: These sections are stained with hematoxylin-eosin and used for histopathological examination. In the initial sections it is unknown which slices are stained and examined.
2 352 Research Letters JAM ACAD DERMATOL FEBRUARY 2017 Table I. Histopathological diagnosis and clinical treatment failure or recurrence Histopathological diagnosis of punch biopsy specimen, n (%)* sbcc nbcc ibcc mnbcc n/mnbcc n/ibcc n/mn/ibcc Total More aggressive subtype missed 90 (77.6) 16 (13.8) 1 (0.9) 1 (0.9) 4 (3.4) 1 (0.9) 3 (2.6) 116 (100.1 y ) 26 (22.4) Clinical treatment failure z or recurrence x Patient Treatment failure or recurrence Location Presence of clinical ulceration Presence of adnexal extension sbcc thickness, mm k Initial treatment Histopathological diagnosis of second punch biopsy specimen { Histopathological diagnosis of excision specimen 1 Recurrence Lower No No FU sbcc sbcc sbcc extremities 2 Recurrence Lower No No 0.20 MAL-PDT sbcc sbcc sbcc extremities 3 No Trunk No No 0.33 MAL-PDT Not performed sbcc sbcc response Head No No 0.74 MAL-PDT n/mnbcc n/mnbcc sbcc 4 Partial response Histopathological diagnosis of punch biopsy specimen # FU, Fluorouracil; ibcc, infiltrative basal cell carcinoma; MAL-PDT, methylaminolevulinate photodynamic therapy; nbcc, nodular basal cell carcinoma; n/mnbcc, micronodular basal cell carcinoma; sbcc, superficial basal cell carcinoma. *Based on histopathological evaluation of 5 levels per punch biopsy specimen, all biopsy specimens based on 1 level evaluation were diagnosed as sbcc. y Numbers do not add up to 100 because of percentages round off. z Clinical treatment failure: partial or no response after initial treatment. x Presence of tumor tissue detected during follow-up after previous tumor clearance. k Largest measurement taken from either the initial or additional hematoxylin-eosin-stained sections. { Extra punch biopsy specimen taken after treatment failure/recurrence for diagnosis and determination of excision margin for treatment. # Based on histopathological evaluation of 5 levels per punch biopsy specimen. (Table I). We did not found an association of tumor thickness, ulceration, or adnexal extension with treatment failure/recurrence. The mean follow-up period was of SD 194 days with a median of 301 days. Hoogedoorn et al 5 found that more than 50% of the treatment failures of superficial BCC, after MAL-PDT, were a result of underdiagnosis of the primary punch biopsy specimen and that in approximately 50% of the recurrences a mixed type BCC was present. Their median follow-up was 2 years, in which they reported higher rates of treatment failures and recurrences. Our limited follow-up time might explain the current lack of association between presence of more aggressive BCC subtypes in punch biopsy specimens and treatment failure/recurrence. This study shows that histologic examination of only 1 level from a punch biopsy specimen leads to underdiagnosis of more aggressive BCC subtypes in biopsy specimens diagnosed as superficial BCCs. We recommend step sectioning to reduce this risk and to prevent undertreatment. We would like to thank J. C. M. Hendriks and E. Bronkhorst for their help with the statistical analysis. Kim P. Nguyen, MD, a G. Jimmy Knuiman, MD, b Piet E. J. van Erp, PhD, a WillekeA.Blokx,MD, PhD, b Malou Peppelman, PhD, a and Marie- Jeanne P. Gerritsen, MD, PhD a Departments of Dermatology a and Pathology, b Radboud University Medical Center, Nijmegen, The Netherlands Drs Nguyen and Knuiman contributed equally to this work. Supplemental material is available at jaad.org. Funding sources: None. Conflicts of interest: None declared. Correspondence to: Kim P. Nguyen, MD, Department of Dermatology, Radboud University Medical Center, PO Box 9101, NL 6500 HB Nijmegen, The Netherlands. T.nguyen@radboudumc.nl REFERENCES 1. Wolberink EA, Pasch MC, Zeiler M, van Erp PE, Gerritsen MJ. High discordance between punch biopsy and excision in
3 JAM ACAD DERMATOL Research Letters 353 establishing basal cell carcinoma subtype: analysis of 500 cases. J Eur Acad Dermatol Venereol. 2013;27(8): Kamyab-Hesari K, Seirafi H, Naraghi ZS, et al. Diagnostic accuracy of punch biopsy in subtyping basal cell carcinoma. J Eur Acad Dermatol Venereol. 2014;28(2): Roozeboom MH, van Kleef L, Arits AH, et al. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sbcc) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU). J Am Acad Dermatol. 2015;73(1): McKay KM, Sambrano BL, Fox PS, Bassett RL, Chon S, Prieto VG. Thickness of superficial basal cell carcinoma (sbcc) predicts imiquimod efficacy: a proposal for a thickness-based definition of sbcc. Br J Dermatol. 2013;169(3): Hoogedoorn L, Hendriks JC, Knuiman GJ, et al. Treatment failure in superficial basal cell carcinoma following treatment with photodynamic therapy: is this a result of underdiagnosis? J Eur Acad Dermatol Venereol Epub 2016/06/04. Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age To the Editor: In the United States, the incidence ratio of basal cell carcinomas (BCCs) to cutaneous squamous cell carcinomas (SCCs) is traditionally taught as 4:1. 1,2 However, the origin of this ratio is unclear, as earlier US-based studies ( published before 1989) report an incidence ratio ranging from 1.4:1 to 9:1. 3 Recently, Rogers and colleagues 4 reported a 1:1 incidence ratio of BCC:SCC using procedural data from the predominantly Caucasian, elderly Medicare fee-for-service population. To evaluate this incidence ratio across all age groups, we performed a retrospective review of BCC and SCC incidence in a northern Californian population. Furthermore, to corroborate our findings, we assessed the lifetime prevalence of BCC and SCC in a larger independent cohort. This study was approved by the institutional review board of Stanford University. To calculate incidences, we analyzed all 8032 diagnostic BCC and SCC dermatopathology reports collected at Stanford Healthcare from 2005 to 2015 (set 1). Patients of all ethnicities were included and 86% were Caucasian. To calculate lifetime prevalence, we used self-reported BCC and SCC cases from 23andMe (set 2), totaling 12,945 patients with BCC, 6579 patients with SCC, and over 250,000 control subjects, all of whom were Caucasian. Accuracy of self-reported answers was previously validated via comparison with medical records in a subset of patients. 5 Analysis of set 1 demonstrates an overall BCC:SCC incidence ratio of 1.4:1 (Table I). In the younger age groups, BCCs heavily outnumber SCCs; however, the Table I. Basal and squamous cell carcinoma biopsy counts stratified by age group, 2005 to 2015 Age, y # [60 Combined BCC SCC BCC:SCC 2.0:1* 5.0:1 2.3:1 1.1:1 1.4:1 BCC, Basal cell carcinoma; SCC, squamous cell carcinoma. Data source: Dermatopathology reports for patients seen and biopsied at Stanford Hospital and Clinics, from June 2005 to June Among patients with BCC, roughly 58% were male and 90% were Caucasian; for SCC cases, these values are 62% and 85%, respectively. Cases defined as recurrences were excluded. For more information about this cohort, please contact the corresponding author (ksarin@stanford.edu). *Small sample size limits accuracy. ratio equalizes as age increases, reaching 1.1:1 in the age group older than 60 years. Set 2 reveals a lifetime prevalence of 11% and 6% for BCC and SCC, respectively, in Caucasians older than 60 years (Table II), consistent with prior studies. 6 As expected for low-mortality diseases, the lifetime prevalence of these cancers increases steadily with age. The overall BCC:SCC incidence ratio of 1.4:1 in this predominantly Caucasian population is significantly lower than 4:1 and corroborates the recent finding of a 1:1 ratio among Medicare beneficiaries. 4 Because these cancers have low mortality and can occur multiple times per individual, the overall lifetime prevalence ratio is expected to approximate the overall incidence ratio yet also demonstrate a slight skew away from the cancer with the greater net increase in incidence across age groups (SCC in this case). Hence, our finding of a 2.0:1 overall lifetime prevalence ratio in an independent cohort substantiates our incidence results. Notably, we included both invasive SCC and SCC in situ under the term SCC. If we exclude SCC in situ from set 1, then the BCC:SCC ratio in the group older than 60 years increases to 1.8:1, which is greater than the corresponding value of 1.2:1 found in the Medicare study. 4 This difference is unsurprising considering that SCC in situ is often treated nonsurgically (and is consequently underreported in Medicare claims data). In addition, the high average ultraviolet index in California likely influenced rates of SCC and SCC in situ in our study. Strengths of this study include large sample size for lifetime prevalence estimates and incidences based on dermatopathology reports. Overall, we demonstrate that the BCC:SCC incidence ratio is much closer to 1:1 than 4:1ethus, clinicians should increase their index of suspicion for SCC, particularly when evaluating older patients.
4 J AM ACAD DERMATOL Research Letters 353.e1 Supplemental Fig 1. Detection of various basal cell carcinoma subtypes and adnexal extension in hematoxylin-eosin-stained sections. A, Superficial component in the initial section of punch biopsy specimen 24 (Supplemental Table II). B to E, In the additional sections of the same punch biopsy specimen (micro-) nodular and infiltrative subtypes are detected. F, Some lesions showed an adnexal extension (arrow). (Original magnification: 35.)
5 353.e2 Research Letters JAM ACAD DERMATOL FEBRUARY 2017 Supplemental Table I. Demographics Patient characteristics N (%) Mean 6 SD Gender Male 43 (48.3) Age, y Tumor characteristics N (%) Mean 6 SD Location Head and neck 15 (12.9) Upper extremities 11 (9.5) Trunk 64 (55.2) Lower extremities 26 (22.4) Size \10 mm 88 (75.9) [10 mm 28 (24.1) Presence of clinical ulceration Yes 1 (0.1) Presence of adnexal extension Yes 13 (11.2) Tumor thickness, mm Initial H&E-stained sections Additional H&E-stained sections * Treatment Imiquimod 23 (19.8) 5-FU 19 (16.4) MAL-PDT 24 (20.7) Excision 50 (43.1) Follow-up time, d y z FU, Fluorouracil; H&E, hematoxylin-eosin; MAL-PDT, methylaminolevulinate photodynamic therapy. *P value when compared with the initial H&E-stained sections was.001. y Until February 1, z Median follow-up period.
6 JAM ACAD DERMATOL Research Letters 353.e3 Supplemental Table II. Histopathological evaluation: presence of additional basal cell carcinoma subtypes* H&E-stained sections in which additional BCC subtypes are present* Punch biopsy specimen Initial H&E First additional level Second additional level Third additional level Fourth additional level 1 No No No No Yes 2 No Yes Yes Yes Yes 3 yz No Yes No No No 4 No No No Yes Yes 5 No No Yes Yes Yes 6 No No Yes No Yes 7 No Yes Yes Yes Yes 8 No No Yes Yes Yes 9 No No No Yes Yes 10 No Yes Yes Yes Yes 11 No Yes Yes Yes Yes 12 No No Yes Yes Yes 13 No No No Yes Yes 14 No Yes Yes Yes No 15 No Yes Yes Yes Yes 16 No No No No Yes 17 yx No No No Yes No 18 No Yes No No Yes 19 No No No Yes Yes 20 No Yes Yes Yes Yes 21 No Yes Yes Yes Yes 22 No Yes No No Yes 23 No No Yes Yes Yes 24 No No Yes Yes Yes 25 No No No No Yes 26 No No No Yes Yes Overall presence of 0 11 (42.3) 14 (53.8) 19 (73.1) 23 (88.5) additional BCC subtypes (%) BCC, Basal cell carcinoma; H&E, hematoxylin-eosin. *Other than superficial basal cell carcinoma subtype. y Other BCC subtype(s) missed when evaluating only second and fourth additional level. z Other BCC subtype(s) missed when evaluating only third and fourth additional level. x Other BCC subtype(s) missed when evaluating only first and fourth additional level.
Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationBasal cell carcinoma diagnosed on Fine-Needle Aspiration Cytology A. Pathological Case Report
Basal cell carcinoma diagnosed on Fine-Needle Aspiration Cytology A Abstract Dr. Madhuri S.Kate 1, Dr. Preeti Jain 2, Dr. Shailesh S. Patne 3 Introduction: Basal cell carcinoma (BCC) is a locally invasive
More informationCommon Benign Lesions and Skin Cancers. 22nd May 2015 Dr Mark Foley
Common Benign Lesions and Skin Cancers 22nd May 2015 Dr Mark Foley Thank you for downloading this file. This intended to supplement the presentation given at the NZ Wound Care Conference, it is not intended
More informationField vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM
Dilemmas and Challenges in Skin Cancer Therapies and Management Field vs Lesional Therapies for AKs 3/2/2019, 9:00-12 AM Roger I. Ceilley, M.D. Clinical Professor of Dermatology The University of Iowa
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationA Retrospective Study of Treatment of Squamous Cell Carcinoma In situ. Övermark, Meri.
https://helda.helsinki.fi A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ Övermark, Meri 2016 Övermark, M, Koskenmies, S & Pitkanen, S 2016, ' A Retrospective Study of Treatment of
More informationDiagnostic concordance among dermatopathologists in basal cell carcinoma subtyping: Results of a study in a skin referral hospital in Tehran, Iran
Original Article Diagnostic concordance among dermatopathologists in basal cell carcinoma subtyping: Results of a study in a skin referral hospital in Azita Nikoo, MD 1 Zahra Naraghi, MD 1 Kambiz Kamyab,
More informationI have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee
I have a skin lump doc! What s next? 12 th August 2017 Dr. Sue-Ann Ho Ju Ee Some thoughts Is this skin cancer? How common is this? How likely is this in this patient? What happens next if it s something
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 6, Issue 5 2016 Article 9 Basal Cell Cancer Carcinoma of the anus: Case Reports and Review of the Literature Christopher Dwyer MD Marc Brozovich MD, FACS, FASCRS
More informationBCC follow up audit. South West Public Health Observatory
BCC follow up audit 2 projects Local Standard Setting in Guideline for follow up of BCC Web based survey local standard to be set Audit of 20 successive cases Aims and To establish the follow up patterns
More informationInteresting Case Series. Aggressive Tumor of the Midface
Interesting Case Series Aggressive Tumor of the Midface Adrian Frunza, MD, Dragos Slavescu, MD, and Ioan Lascar, MD, PhD Bucharest Emergency Clinical Hospital, Bucharest University School of Medicine,
More informationMohs surgery for the nail unit
Mohs surgery for the nail unit olivier.cogrel@chu-bordeaux.fr Dermatologic surgery, Mohs surgery and lasers unit CHU Bordeaux, France Squamous cell carcinoma +++ Acral lentiginous melanoma Lichte et al.
More informationBasal cell carcinoma 5/28/2011
Goal of this Presentation A practical approach to the diagnosis of cutaneous carcinomas and their mimics Thaddeus Mully, MD University of California San Francisco To review common non-melanoma skin cancers
More informationSkin Cancer of the Nose: Common and Uncommon
Skin Cancer of the Nose: Common and Uncommon Mark Russell, M.D. Associate Professor of Dermatology, Otolaryngology, and Pathology University of Virginia Objectives Review clinical presentations of select
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationCASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge
CASE REPORT Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge Yuri T. Jadotte, MD, a Navér A. Sarkissian, MD, PhD, b,c Helchem Kadire, MD, c and W. Clark Lambert, MD, PhD b,c
More informationEvidence for Mohs surgery
Evidence for Mohs surgery Simone van der Geer Dermatologist, Mohs surgeon Secretary of the ESMS Excision Mohs 3-5 mm clinical margin 0,1% margin control (Abide, The meaning of surgical margins. Plast Reconstr
More informationCutaneous Adnexal Tumors
Cutaneous Adnexal Tumors Lesions with Predominant Follicular Differentiation Special Emphasis on Basal Cell Carcinoma 2014-04-01 Prof. Dr. med. Katharina Glatz Pathologie Cutaneous Adnexal Tumors Hair
More informationNonmelanoma skin cancers
Skin cancer Philip Clarke Nonmelanoma skin cancers Treatment options Background Australia has one of the highest skin cancer rates in the world. Early detection and treatment of skin cancer is vital to
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationJuly 2012 SKIN SURGERY SERVICE BRIEFING NOTES
SKIN SURGERY SERVICE BRIEFING NOTES Introduction The WBoP PHO has an agreement with the BoP District Health Board to deliver the Skin Surgery Service. The current period will expire on 30 June 2012 and
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationMapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery
Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery Robert Glinert, MD and Song Q. Zhao, MD, Ph.D., MPH Department
More informationSkin disorders. Basal cell carcinoma December 2009 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig ...
December 29 Anthony Ormerod, Sanjay Rajpara, and Fiona Craig.................................................. ABSTRACT INTRODUCTION: (BCC) is the most common form of skin cancer, predominantly affecting
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: September 11, 2017 Report Length: 29 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Imiquimod for the Treatment of Basal Cell or Squamous Cell Carcinoma: A Review of Clinical Effectiveness and Cost-Effectiveness Service Line:
More informationLarge majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest risk.
Basics of Skin Cancer Detection and Treatment of Non- Melanoma Skin Cancers Large majority caused by sun exposure Often sun exposure before age 20 Persons who burn easily and tan poorly are at greatest
More informationGlenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine
Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new
More informationLiving Beyond Cancer Skin Cancer Detection and Prevention
Living Beyond Cancer Skin Cancer Detection and Prevention Cutaneous Skin Cancers Identification Diagnosis Treatment options Prevention What is the most common cancer in people? What is the most common
More informationUsefulness of Dermatoscopy for the Preoperative Assessment of the Histopathologic Aggressiveness of Basal Cell Carcinoma
HS Kim, et al Ann Dermatol Vol. 27, No. 6, 2015 http://dx.doi.org/10.5021/ad.2015.27.6.682 ORIGINAL ARTICLE Usefulness of Dermatoscopy for the Preoperative Assessment of the Histopathologic Aggressiveness
More informationLearning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating
Learning Objectives Skin Cancers: Preventing, Screening and Treating Robert A. Baldor, MD, FAAFP Professor, Family Medicine & Community Health University of Massachusetts Medical School Distinguish the
More informationInterrater and intrarater agreement of confocal microscopy imaging in diagnosing and subtyping basal cell carcinoma
DOI: 10.1111/jdv.14771 JEADV ORIGINAL ARTICLE Interrater and intrarater agreement of confocal microscopy imaging in diagnosing and subtyping basal cell carcinoma D.J. Kadouch, 1, *, A.S.E. van Haersma
More informationLimitations of nonsurgical treatment modalities. Nonsurgical Treatments (Table V) 1/31/2018
DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY James M. Grichnik M.D. Ph.D. Alternative Therapies James M Grichnik MD PhD Director, Scully-Welsh Cancer Center Indian River Medical Center grichnik@irmc.cc
More informationPolicy #: 127 Latest Review Date: June 2011
Name of Policy: Mohs Micrographic Surgery Policy #: 127 Latest Review Date: June 2011 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates. Background/Definitions:
More informationDermoscopy: Recognizing Top Five Common In- Office Diagnoses
Dermoscopy: Recognizing Top Five Common In- Office Diagnoses Vu A. Ngo, DO Department of Family Medicine and Dermatology Choctaw Nation Health Services Authority Learning Objectives Introduction to dermoscopy
More informationSkin Cancer 101: Diagnosis and Management of the Most Common Cancer
Skin Cancer 101: Diagnosis and Management of the Most Common Cancer Sarah Patton, PA-C, MSHS Skin Surgery Center www.skinsurgerycenter.com Seattle/Bellevue, WA Skin cancer Skin cancer is by far the most
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationCLEAR CELL BASAL CELL CARCINOMA- AN UNUSUAL ENTITY IN AN INDIAN MALE
Indian Journal of Medical s ISSN: 2319 3832(Online) CLEAR CELL BASAL CELL CARCINOMA- AN UNUSUAL ENTITY IN AN INDIAN MALE * Cheena Garg 1, Arjun Agarwal 2, Bushra Siddiqui 3, Shahbaz Faridi 4, 1 Department
More informationMING H. JIH, MD,PHD, PAUL M. FRIEDMAN, MD,LEONARD H. GOLDBERG, MD,AND ARASH KIMYAI-ASADI, MD. Methods Phase I: Retrospective (Group 1)
Curettage prior to Mohs Micrographic Surgery for Previously Biopsied Nonmelanoma Skin Cancers: What Are We Curetting? Retrospective, Prospective, and Comparative Study MING H. JIH, MD,PHD, PAUL M. FRIEDMAN,
More informationScottish Medicines Consortium
Scottish Medicines Consortium imiquimod 5% cream (Aldara) No. (385/07) Meda Pharmaceuticals Ltd 04 April 2008 The Scottish Medicines Consortium has completed its assessment of the above product and advises
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationTopical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary
Topical Diclofenac Gel, Fluorouracil Cream, Imiquimod Cream, and Ingenol Gel Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-8 Topical Diclofenac Gel Indication
More information(SCARD) At any time to clarify any issues you can contact us by on
The SCCANZ Skin Cancer Audit and Research Database (SCARD) TO USE THE PROGRAM At any time to clarify any issues you can contact us by email on support@skincanceraudit.com The Notice Board on the home-page
More informationBreslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma
Research DOI: 10.6003/jtad.16104a2 Breslow Thickness and Clark Level Evaluation in Albanian Cutaneous Melanoma Daniela Xhemalaj, MD, Mehdi Alimehmeti, MD, Susan Oupadia, MD, Majlinda Ikonomi, MD, Leart
More informationPeriocular Malignancies
Periocular Malignancies Andrew Gurwood, O.D., F.A.A.O., Dipl. Marc Myers, O.D., F.A.A.O. Drs. Myers and Gurwood have no financial interests to disclose. Course Description Discussion of the most common
More informationIT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY
IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY Skin, Bones, and other Private Parts Symposium Dermatology Lectures by Debra Shelby, PhD, DNP, FNP-BC, FADNP, FAANP Debra Shelby,
More information1 Cancer Council Queensland, Brisbane, Queensland, Australia.
Title: Diagnosis of an additional in situ does not influence survival for patients with a single invasive : A registry-based follow-up study Authors: Danny R Youlden1, Kiarash Khosrotehrani2, Adele C Green3,4,
More informationIntraoperative Dermoscopy for Identification of Early Basal Cell Carcinomas in Basal Cell Nevus Syndrome
Intraoperative Dermoscopy for Identification of Early Basal Cell Carcinomas in Basal Cell Nevus Syndrome Disclosures I have no industry related, financial, or other disclosures Goals Discuss the clinical
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationPeriocular skin cancer
Periocular skin cancer Information for patients Skin cancer involving the skin of the eyelid or around the eye is called a periocular skin cancer. Eyelid skin cancers occur most often on the lower eyelid,
More informationCase Presentation Protocol 2018 Hot Spots in Dermatology
Metastatic 1 Running Head: METASTATIC BASAL CELL CARCINOMA Case Presentation Protocol 2018 Hot Spots in Dermatology A Case Study of Metastatic BCC Marianna F. Karewicz, NP Mentor: Dr. Roman W. Glamb, MD
More informationGlenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine
Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment
More informationCase Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor
Case Reports in Medicine Volume 2015, Article ID 742920, 4 pages http://dx.doi.org/10.1155/2015/742920 Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Omer Alici,
More informationDiagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions Diagnostics guidance Published: 11 November 2015 nice.org.uk/guidance/dg19 NICE 2018. All rights reserved. Subject to Notice of
More informationCorporate Medical Policy
Corporate Medical Policy Dermatologic Applications of Photodynamic Therapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: dermatologic_applications_of_photodynamic_therapy 10/2003
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More information1) Photodynamic therapy with topical 5 aminolevulinic acid is considered medically necessary and is covered for the treatment of:
Medical Policy Title: Photodynamic Therapy ARBenefits Approval: 10/26/2011 for Dermatologic Conditions Effective Date: 01/01/2012 Document: ARB0282:02 Revision Date: 03/20/2013 Code(s): 96567 Photodynamic
More informationDisclosures. I have no conflicts of interest to disclose
Disclosures I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco 2
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationFor additional information on meeting the criteria for Mohs, see Appendix 2.
Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs
More informationThe Old, The New and the Reemerging-HIV Dermatology. Toby Maurer, MD
The Old, The New and the Reemerging-HIV Dermatology Toby Maurer, MD 1 Psoriasis Widespread psoriasis, especially if it was once stable, predicts falling CD4 count?resistance to ART??Non-adherence? Tx:
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #440: Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time Pathologist to Clinician National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS
More informationNew and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ
New and Emerging Therapies: Non-Melanoma Skin Cancers David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ Disclosure Research Grant form Sensus Superficial Radiation Therapy (SRT) Modern
More informationALASKA ARIZONA IDAHO MONTANA NORTH DAKOTA OREGON SOUTH DAKOTA UTAH WASHINGTON WYOMING
The following policy (L35704) has been archived by Alpha II. Many policies are part of a larger jurisdiction, than is indicated by the policy. This policy covers the following states: ALASKA ARIZONA IDAHO
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationCase Report Clear Cell Basal Cell Carcinoma
SAGE-Hindawi Access to Research Volume 2011, Article ID 386921, 4 pages doi:10.4061/2011/386921 Case Report Clear Cell Basal Cell Carcinoma Deba P. Sarma, 1 Daniel Olson, 1 Jennifer Olivella, 1 Tracey
More informationSTUDY. Differences in Biopsy Techniques of Actinic Keratoses by Plastic Surgeons and Dermatologists. the most common reasons
STUDY Differences in Biopsy Techniques of Actinic Keratoses by Plastic Surgeons and Dermatologists A Histologically Controlled Pilot Study Klaus Sellheyer, MD; Wilma F. Bergfeld, MD Objective: To compare
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #440: Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time Pathologist to Clinician National Quality Strategy Domain: Communication and Care Coordination Meaningful
More informationHistopathology: Cervical HPV and neoplasia
Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about
More informationExtreme dermatoheliosis: How to approach the severely sun damaged patient
Extreme dermatoheliosis: How to approach the severely sun damaged patient Anokhi Jambusaria MD, MSCE Staff Dermatologist Baylor Scott and White Health Round Rock, TX I have no relevant conflicts of interest
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationTracking skin cancers and melanoma at the microscopic level
Tracking skin cancers and melanoma at the microscopic level Rosalie Elenitsas, M.D. Professor of Dermatology Director of Dermatopathology Hospital of the University of Pennsylvania May 12, 2017 Outline
More informationDisclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose
Disclosures Melanoma and Non melanoma Skin Cancer: What You Need to Know I have no conflicts of interest to disclose Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department
More informationOBSERVATION. Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ With a High-Energy Pulsed Carbon Dioxide Laser
OBSERVATION Treatment of Superficial Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ With a High-Energy Pulsed Carbon Dioxide Laser Tatyana R. Humphreys, MD; Rajwant Malhotra, MD; Mark J. Scharf,
More informationMaligna Melanoma and Atypical Fibroxanthoma: An Unusual Collision Tumour G Türkcü 1, A Keleş 1, U Alabalık 1, D Uçmak 2, H Büyükbayram 1 ABSTRACT
Maligna Melanoma and Atypical Fibroxanthoma: An Unusual Collision Tumour G Türkcü 1, A Keleş 1, U Alabalık 1, D Uçmak 2, H Büyükbayram 1 ABSTRACT Two different neoplasia in the same biopsy material called
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationSkin NCG (Anglia East & Anglia West)
Guidelines for the Management of Basal Cell Carcinoma Skin NCG (Anglia East & Anglia West) Author: N R Telfer, G B Colver and C A Morton Approved by: Anglia Cancer Network Skin NCG Approved on: Reviewed
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationDeveloping the next generation of dermatology products to treat serious skin diseases
Developing the next generation of dermatology products to treat serious skin diseases Tom Wiggans Chairman and Chief Executive Officer www.peplin.com Forward Looking Statements This presentation contains
More informationSingle Technology Appraisal (STA) Vismodegib for treating basal cell carcinoma [ID1043]
Single Technology Appraisal (STA) Vismodegib for treating basal cell carcinoma [ID1043] Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationPhotodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions
Photodynamic Therapy for the Treatment of Actinic Keratoses and Other Skin Lesions Policy Number: Original Effective Date: MM.02.016 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationSkin SSG (Anglia East & Anglia West)
Skin SSG (Anglia East & Anglia West) Author: Dr Jennifer Garioch, Consultant Dermatologist Dr Pamela Todd, Consultant Dermatologist Approved by: Anglia Cancer Network Skin NSSG Approved on: Reviewed and
More informationFDA INDICATIONS Mohs surgery is a procedure and is not regulated by the Food and Drug Administration.
Subject: Micrographic (Mohs) Surgery for Cancerous and Noncancerous Lesions Guidance Number: MCG-135 Revision Date(s): Original Effective Date: 6/26/13 Medical Coverage Guidance Approval Date: 6/26/13
More informationClinical characteristics
Skin Cancer Fernando Vega, MD Seattle Healing Arts Clinical characteristics Precancerous lesions Common skin cancers ACTINIC KERATOSIS Precancerous skin lesions Actinic keratoses Dysplastic melanocytic
More informationPatient Guide. The precise answer for tackling skin cancer. Brachytherapy: Because life is for living
Patient Guide Brachytherapy: The precise answer for tackling skin cancer Because life is for living Overview of skin cancer Skin cancer is the most common cancer worldwide. In fact more people are diagnosed
More informationMalignant non-melanocytic lesions
Malignant non-melanocytic lesions Course C023: Fundamentals of Dermoscopy March 4, 2019, 11:20 AM - 11:50 PM Room: 146B Jason B. Lee, MD Professor & Vice Chair Director of Dermatopathology & Pigmented
More informationDual Wavelength Phototherapy System
Dual Wavelength Phototherapy System The AKLARUS Blue and Red Combination System is an effective, drugfree alternative for treating acne & photodamaged skin. The non-invasive Aklarus treatment has been
More informationAspects of skin cancer diagnosis in clinical practice
Aspects of skin cancer diagnosis in clinical practice Ahnlide, Ingela 2015 Document Version: Publisher's PDF, also known as Version of record Link to publication Citation for published version (APA): Ahnlide,
More informationTOPICAL TREATMENT OF ACTINIC KERATOSIS
TOPICAL TREATMENT OF ACTINIC KERATOSIS Gary Goldenberg, MD Goldenberg Dermatology, PC Assistant Clinical Professor of Dermatology The Icahn School of Medicine at Mount Sinai Hospital Conflicts of Interest
More informationRCGP and Cancer Research UK Workshop. Hilton Newcastle Gateshead, Bottle Bank, Gateshead, NE8 2AR 13 th July 2017
Hilton Newcastle Gateshead, Bottle Bank, Gateshead, NE8 2AR 13 th July 2017 Dr Richard Roope RCGP and Cancer Research UK Cancer Clinical Champion Senior Clinical Advisor Cancer Research UK How can GPs
More informationCLINICAL SCIENCE. doi: /S
CLINICS 2009;64(10):961-6 CLINICAL SCIENCE TREATMENT OF CUTANEOUS TUMORS WITH TOPICAL 5% IMIQUIMOD CREAM Sabrina Sisto Alessi, Jose Antonio Sanches, Walmar Roncalli de Oliveira, Maria Cristina Messina,
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationBASAL CELL CARCINOMA WITH ECCRINE DIFFERENTIATION: A RARE ENTITY Divvya B 1, Rehana Tippoo 2, P. Viswanathan 3, B. Krishnaswamy 4, A.
BASAL CELL CARCINOMA WITH ECCRINE DIFFERENTIATION: A RARE ENTITY Divvya B 1, Rehana Tippoo 2, P. Viswanathan 3, B. Krishnaswamy 4, A. Anvar Ali 5 HOW TO CITE THIS ARTICLE: Divvya B, Rehana Tippoo, P. Viswanathan,
More information